Editas Medicine (EDIT) Stock Price, Quote & News

Company Profile

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in No...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 401 9000

Website: www.editasmedicine.com

Address:

11 Hurley Street, Cambridge, United States

3DBuilds Dec. 26 at 10:35 PM

$BMY $CRBU $EDIT $JNJ $NTLA

0 · Reply

abcdzepeda Dec. 26 at 7:51 AM

$EDIT Merry Christmas everyone!

0 · Reply

ThamesTrader Dec. 25 at 9:12 AM

$EDIT The valuation debate now centers on reliability of delivery, amid evolving funding conditions and shifting competitive responses. Proof points carry more weight than guidance alone.

1 · Reply

DrQuonsShaggyBALLS Dec. 24 at 7:36 PM

$EDIT

0 · Reply

DrQuonsShaggyBALLS Dec. 24 at 7:35 PM

$EDIT how is this still around. They had the patents HANDED TO THEM when they were founded and all they've done since is FLOUNDER.

0 · Reply

Frankness100 Dec. 23 at 4:52 PM

$EDIT just EOY portfolio re-balancing/ tax harvesting?

0 · Reply

Whoami1989 Dec. 23 at 4:42 PM

$EDIT such as shitty loser!!! what fuck is wrong with this mf

0 · Reply

Whoami1989 Dec. 23 at 3:17 PM

$EDIT any idiot wants to buy? such a fucking loser

0 · Reply

StockBraker Dec. 21 at 1:45 PM

$EDIT For what it's worth... https://www.trefis.com/data/companies/EDIT/no-login-required/PlghKJWX/Can-Editas-Medicine-Stock-Recover-If-Markets-Fall-

0 · Reply

3DBuilds Dec. 19 at 11:27 PM

$CRBU $NTLA $EDIT $JNJ $BMY Amazing 🤩 Jennifer and Zuckerberg next year 💯 things are gunna get Amazing 🌎

0 · Reply

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

Nov 3, 2025, 9:00 AM EST - 7 weeks ago

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

Oct 14, 2025, 6:18 PM EDT - 2 months ago

Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm?

Oct 9, 2025, 11:01 AM EDT - 2 months ago

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Oct 6, 2025, 9:00 AM EDT - 2 months ago

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

Sep 2, 2025, 11:14 AM EDT - 4 months ago

Editas Medicine, Inc. - Special Call

Sep 2, 2025, 7:00 AM EDT - 4 months ago

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

Aug 28, 2025, 4:01 PM EDT - 4 months ago

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

Aug 27, 2025, 9:00 AM EDT - 4 months ago

Editas Medicine to Participate in Upcoming Investor Conferences

Aug 12, 2025, 4:01 PM EDT - 4 months ago

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

Jun 12, 2025, 2:01 AM EDT - 7 months ago

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

May 20, 2025, 5:47 AM EDT - 7 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC AUTL CAPR CLPT NTLA VANI VERV

May 14, 2025, 2:17 PM EDT - 8 months ago

Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript)

May 14, 2025, 9:31 AM EDT - 8 months ago

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

May 14, 2025, 7:01 AM EDT - 8 months ago

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

May 13, 2025, 7:01 AM EDT - 8 months ago

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

May 12, 2025, 4:30 PM EDT - 8 months ago

Editas Medicine Announces First Quarter 2025 Results and Business Updates

May 12, 2025, 4:01 PM EDT - 8 months ago

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

May 5, 2025, 4:01 PM EDT - 8 months ago

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

Apr 28, 2025, 4:31 PM EDT - 8 months ago

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Mar 20, 2025, 4:01 PM EDT - 10 months ago

Editas Medicine Announces Chief Financial Officer Transition

Mar 11, 2025, 4:07 PM EDT - 10 months ago

Editas Medicine, Inc. (EDIT) Barclays 27th Annual Global Healthcare Conference (Transcript)

Mar 10, 2025, 12:19 PM EDT - 10 months ago

Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (Transcript)

Mar 5, 2025, 4:05 PM EST - 10 months ago

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

Mar 3, 2025, 5:01 PM EST - 10 months ago

Editas Medicine, Inc. (EDIT) TD Cowen 45th Annual Health Care Conference Transcript

Feb 24, 2025, 9:00 AM EST - 10 months ago

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

Jan 17, 2025, 12:20 PM EST - 1 year ago

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

NTLA

Jan 15, 2025, 4:35 PM EST - 1 year ago

Editas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript)

Jan 13, 2025, 9:00 AM EST - 1 year ago

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Jan 6, 2025, 9:00 AM EST - 1 year ago

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 13, 2024, 6:44 AM EST - 1 year ago

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026

Dec 12, 2024, 6:03 PM EST - 1 year ago

Editas to reduce about 65% of its workforce over the next six months

Dec 12, 2024, 4:00 PM EST - 1 year ago

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Dec 9, 2024, 12:00 PM EST - 1 year ago

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Dec 3, 2024, 10:52 PM EST - 1 year ago

Editas Medicine, Inc. (EDIT) 7th Annual Evercore HealthCONx Conference (Transcript)

Nov 25, 2024, 12:59 PM EST - 1 year ago

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts

Nov 19, 2024, 7:53 PM EST - 1 year ago

Editas Medicine, Inc. (EDIT) Presents at Stifel 2024 Healthcare Conference (Transcript)

Nov 4, 2024, 7:30 AM EST - 1 year ago

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Oct 22, 2024, 11:45 AM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript

Oct 21, 2024, 4:30 PM EDT - 1 year ago

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

Oct 18, 2024, 4:01 PM EDT - 1 year ago

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

Oct 7, 2024, 3:33 PM EDT - 1 year ago

Editas Medicine (EDIT) Shares Plunge Amid Biotech Sector Fluctuations

Oct 6, 2024, 2:00 PM EDT - 1 year ago

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

AMGN BIIB BLUE BMY CRSP EXAS NTLA

Oct 3, 2024, 6:00 PM EDT - 1 year ago

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

Oct 1, 2024, 7:53 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Chardan's 8th Annual Genetic Medicines Conference (Transcript)

Sep 25, 2024, 11:46 AM EDT - 1 year ago

Editas Medicine: A Risk/Reward Worth Considering

Sep 17, 2024, 5:26 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) 2024 Cantor Global Healthcare Conference (Transcript)

Sep 5, 2024, 11:19 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Presents at Wells Fargo 2024 Healthcare Conference (Transcript)

Sep 4, 2024, 7:17 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

Aug 7, 2024, 12:03 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Q2 2024 Earnings Call Transcript

3DBuilds Dec. 26 at 10:35 PM

$BMY $CRBU $EDIT $JNJ $NTLA

0 · Reply

abcdzepeda Dec. 26 at 7:51 AM

$EDIT Merry Christmas everyone!

0 · Reply

ThamesTrader Dec. 25 at 9:12 AM

$EDIT The valuation debate now centers on reliability of delivery, amid evolving funding conditions and shifting competitive responses. Proof points carry more weight than guidance alone.

1 · Reply

DrQuonsShaggyBALLS Dec. 24 at 7:36 PM

$EDIT

0 · Reply

DrQuonsShaggyBALLS Dec. 24 at 7:35 PM

$EDIT how is this still around. They had the patents HANDED TO THEM when they were founded and all they've done since is FLOUNDER.

0 · Reply

Frankness100 Dec. 23 at 4:52 PM

$EDIT just EOY portfolio re-balancing/ tax harvesting?

0 · Reply

Whoami1989 Dec. 23 at 4:42 PM

$EDIT such as shitty loser!!! what fuck is wrong with this mf

0 · Reply

Whoami1989 Dec. 23 at 3:17 PM

$EDIT any idiot wants to buy? such a fucking loser

0 · Reply

StockBraker Dec. 21 at 1:45 PM

$EDIT For what it's worth... https://www.trefis.com/data/companies/EDIT/no-login-required/PlghKJWX/Can-Editas-Medicine-Stock-Recover-If-Markets-Fall-

0 · Reply

3DBuilds Dec. 19 at 11:27 PM

$CRBU $NTLA $EDIT $JNJ $BMY Amazing 🤩 Jennifer and Zuckerberg next year 💯 things are gunna get Amazing 🌎

0 · Reply

Whoami1989 Dec. 19 at 9:21 PM

$EDIT wow what a beautiful witch

0 · Reply

3DBuilds Dec. 19 at 8:39 PM

$EDIT lol bro 😎 it’s coming but see I got this but I also got Intellia and Caribou 💯 I think caribou is going to be really strong 💰 🌎

0 · Reply

Whoami1989 Dec. 19 at 7:52 PM

$EDIT Where are idiotic cheer leaders?

0 · Reply

Whoami1989 Dec. 19 at 3:28 PM

$EDIT market rallies for 200 years this fpos is down to the south

0 · Reply

Whoami1989 Dec. 19 at 3:12 PM

$EDIT Never has a chance dumb asses

0 · Reply

VVDB Dec. 19 at 12:37 AM

$CRSP, $NTLA, $BEAM, $EDIT Bullish! KL Muldoon's success so far is very promising- www.youtube.com/watch?v=hwTSgFpWzQ8

0 · Reply

SuperGreenToday Dec. 18 at 11:11 PM

$EDIT Share Price: $2.36 Contract Selected: May 15, 2026 $1.5 Calls Buy Zone: $0.55 – $0.68 Target Zone: $0.96 – $1.18 Potential Upside: 65% ROI Time to Expiration: 147 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Whoami1989 Dec. 18 at 9:01 PM

$EDIT fking shame company

0 · Reply

Whoami1989 Dec. 18 at 8:04 PM

$EDIT anyone buys? if you do, you are extremely smart. give me some of your gene

0 · Reply

Whoami1989 Dec. 18 at 7:55 PM

$EDIT None of you dumb asses sees any worst stock like this one

0 · Reply

Whoami1989 Dec. 18 at 7:48 PM

$EDIT if you say that it is not a fpos, you are as dumb as fk

0 · Reply

Whoami1989 Dec. 18 at 7:47 PM

$EDIT tell me whether this is not a fpos.

0 · Reply

Market Cap	211.83M
Revenue (ttm)	32.31M
Net Income (ttm)	-237.09M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-733.80%
Debt to Equity Ratio	0.00

Volume	1,260,800
Avg Vol	2,019,170
Day's Range	N/A - N/A
Shares Out	97.62M
Stochastic %K	10%
Beta	2.44
Analysts	Sell
Price Target	$4.94